Dec 02,2020

Virta Health Raises $65 Million Series D to Scale Type 2 Diabetes Reversal Treatments

Virta Health, the first company dedicated to reversing type 2 diabetes without medications or surgery, today announced that it has raised $65 million in Series D funding. Led by Sequoia Capital Global Equities, the financing will support the growing demand for Virta’s reversal treatments for type 2 diabetes and other chronic metabolic conditions.

FUNDING SERIES D
View Analyst & Ambassador Comments
Go to original news
Dec 03,2020

German startup Perfood closes €5M Series A for migraine therapy

German digital therapeutic startup, Perfood, has received €5 million in a Series A funding round to launch its first prescription therapeutic sinCephalea for the treatment of migraines and to prepare for the expansion of the technology into other countries. This includes the conduction of clinical studies to advance its digital therapeutics products. Boehringer Ingelheim Venture Fund led the round and is joined by German family office UV-Cap and Swiss investment platform investiere.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Dec 08,2020

Freespira Finalizes $10 Million Financing to Support Commercialization of Digital Therapeutic for Treatment of Panic Disorder and PTSD

Freespira, Inc., maker of the first FDA-cleared digital therapeutic that significantly reduces or eliminates symptoms of panic attacks, panic disorder and post-traumatic stress disorder (PTSD) in only 28 days, announced it has completed a $10 million capital raise led by Lightspeed Venture Partners. Joining the financing round, the largest in the company’s history, were previous investors Aphelion Capital, Medvest Capital, and Freespira Chairman, Russell Siegelman.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Dec 08,2020

Pear Therapeutics Completes $80 million Series D Financing

Pear Therapeutics, Inc., (“Pear” or the “Company”) today announced that it has successfully closed an $80 million Series D financing led by SoftBank Vision Fund 21 with participation from existing investors including Temasek, 5AM Ventures, Arboretum Ventures, JAZZ Venture Partners, Novartis, CrimsoNox, and EDBI, and new investors, Forth Management, Pilot House, Sarissa Capital, Shanda Group, and QUAD Investment Management. Pear will use the financing to accelerate reimbursement coverage for its three commercial products, creating the first market access pathway in the PDT industry.

FUNDING SERIES D
View Analyst & Ambassador Comments
Go to original news
Dec 16,2020

Lucine for Chronic Pain Raises $6.6 million Funding

Lucine, a French startup offering a digital therapeutic for chronic pain, has raised $6.6 million (€5.5 million) in new funds from Kurma Partners, Bpifrance's Autonomous Patient Fund, BNP Paribas Développement, Aquiti Gestion and Irdi Soridec. The company's app uses face recognition and AI to quantify the user's pain and deliver personalized treatments such as cognitive behavioral therapy. With the new money, Lucine said it will be putting together new clinical studies for its product.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Dec 16,2020

Digital Therapeutics Startup S-Alpha Therapeutics Raises $2.7M in Seed Funding

S-Alpha Therapeutics (“S-Alpha” Seung Eun Choi, CEO), a digital therapeutics startup, completed a $2.7 Million USD (3 Billion KRW) seed round of funding from Hana Ventures, STIC Ventures, AJU IB Investment, SJ Investment Partners, and TONY Investment. This seed round follows an initial strategic investment from LegoChem Biosciences in February 2020. The company intends to use funds to execute clinical trials in the US to study their development stage digital therapeutic application intended to treat eye disease.

FUNDING SEED
View Analyst & Ambassador Comments
Go to original news
Dec 18,2020

Voluntis obtains €3 million of additional non-dilutive loans and optimizes its existing financing

Voluntis , a leader in the field of digital therapeutics, announces that it has been granted new state-guaranteed loans (Prêt Garanti par l’Etat, or PGE in France) for a total amount of €3 million from BNP Paribas and Crédit du Nord and the optimization of the Company’s financial structure.

FUNDING DEBT FINANCE
View Analyst & Ambassador Comments
Go to original news
Dec 20,2019

DarioHealth Announces Closing of $21.3 Million Private Placement

DarioHealth Corp. (Nasdaq: DRIO) ("DarioHealth" or the "Company"), a pioneer in the global digital therapeutics market, announced today that it has closed on a private placement of convertible preferred stock to institutional and private investors. The Company received aggregate gross proceeds of approximately $21.3 million, before deducting placement agent fees and other offering expenses payable by the Company.

FUNDING POST-IPO EQUITY
View Analyst & Ambassador Comments
Go to original news
Nov 08,2019

Digital therapeutics company Jogo Health raises $2 million

Jogo Health (Bridgewater, N.J.) — a startup with a prescription digital therapeutics approach to train the brain to restore muscle function — has raised more than $2 million. Jogo Health’s Jogo technology includes wireless s/EMG sensors for feedback and a patent-protected mobile app with treatment protocols and games that can be adapted for muscle relaxation, movement coordination, and neuromuscular reeducation.

FUNDING SEED
View Analyst & Ambassador Comments
Go to original news
Oct 10,2019

Intermountain Ventures invest in Omada Health to expand relationship

Intermountain Ventures, the strategic investment arm of Intermountain Healthcare has invested in digital care leader Omada Health. The announcement expands the relationship with Intermountain Healthcare that began five years ago in 2016 and comes off the heels of Omada’s recent $73M funding round. The Omada Program became a covered benefit for Intermountain employees and their adult dependents in 2019.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Subscribe to FUNDING